Enoxaparin has strong clinical evidence supporting its use across a broad spectrum of indications, including thromboprophylaxis, VTE treatment, and management of unstable angina and non-Q wave myocardial infarction.
Answers are grounded in this paper and cite their sources.
Supports enoxaparin across VTE and ACS indications; leaves open comparative efficacy versus newer agents in contemporary cohorts.
Enoxaparin has strong clinical evidence that supports its license in a broad spectrum of therapeutic indications, including thromboprophylaxis in surgical patients, medical patients bedridden because of acute illness, the once-daily treatment of venous thromboembolism and the treatment of unstable angina and non-Q wave myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Harvey et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: